KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Capital Leases (2016 - 2025)

Historic Capital Leases for Vertex Pharmaceuticals (VRTX) over the last 15 years, with Q1 2025 value amounting to $111.4 million.

  • Vertex Pharmaceuticals' Capital Leases fell 6918.4% to $111.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $111.4 million, marking a year-over-year decrease of 6918.4%. This contributed to the annual value of $112.8 million for FY2024, which is 7000.8% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Capital Leases stood at $111.4 million for Q1 2025, which was down 6918.4% from $112.8 million recorded in Q4 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Capital Leases peaked at $530.3 million during Q1 2021, and registered a low of $111.4 million during Q1 2025.
  • In the last 5 years, Vertex Pharmaceuticals' Capital Leases had a median value of $417.6 million in 2023 and averaged $386.1 million.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Capital Leases surged by 54.74% in 2021, and later plummeted by 7079.17% in 2024.
  • Vertex Pharmaceuticals' Capital Leases (Quarter) stood at $509.8 million in 2021, then decreased by 15.5% to $430.8 million in 2022, then dropped by 12.7% to $376.1 million in 2023, then crashed by 70.01% to $112.8 million in 2024, then dropped by 1.24% to $111.4 million in 2025.
  • Its last three reported values are $111.4 million in Q1 2025, $112.8 million for Q4 2024, and $114.0 million during Q3 2024.